Abstract:Background For patients taking factor Xa (FXa) inhibitors who have life-threatening bleeding, emergency surgery, drug interactions, etc., a rapid and precise assay is needed to monitor for potential medication failure, to assess safety during periprocedural anticoagulation management, and to manage the care of chronically anticoagulated patients. Anti-factor Xa (anti-Xa) activity assays have been recommended in guidelines, but the evaluation of different calibrations of anti-Xa activity assays and the data on the recommended range are still limited, especially in the Asian population. Methods This is a nationwide multicenter methodology exploratory study in an Asian population, including nine hospitals from Beijing, Shanghai, Liaoning, Shandong, Jiangsu, Anhui, Henan, Chongqing, and Fujian. A total of 485 healthy volunteers and 219 patients taking rivaroxaban or apixaban (single dose) were enrolled in the study. High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS) was employed to detect plasma rivaroxaban and apixaban. The prothrombin time (PT), activated partial thromboplastin time (APTT), and levels of anti-Xa activity were tested as pharmacodynamic parameters in plasma samples. We evaluated the correlation of anti-Xa activity and blood concentration via HPLC-MS, and then compared the two methods of target drug-calibrated and low-molecular-weight heparin (LMWH)-antithrombin–calibrated anti-Xa activity. Correlations between variables were examined using Pearson’s correlation analysis. Logistic regression was applied to evaluate significant differences in anti-Xa activity and blood concentration, using models adjusted by baseline characteristics. Results The results suggested anti-Xa activity had better correlation with blood concentrations of apixaban and rivaroxaban than APTT and PT ( p < 0.001). Target drug-calibrated anti-Xa activity had better correlation with HPLC-MS results at every dose level and blood collection time ( p < 0.001). The expected concentrations (ng/mL) derived from rivaroxaban-calibrated assays of rivaroxaban 10 mg, 15 mg, and 20 mg were about 210, 330, and 270 at peak concentrations, and 28, 44, and 58, respectively, at the trough concentrations. Conclusions In this study, we confirm that target drug calibration of anti-Xa activity is a better quantitative detection method for oral direct FXa inhibitors than LMWH-calibrated anti-Xa activity in clinical practice, and expected peak–trough levels are recommended for the Asian population.

In Vivo Real-Time Monitoring of Anti-Factor Xa Level Using a Microdialysis-Coupled Microfluidic Device

A microfluidic hemostatic diagnostics platform: Harnessing coagulation-induced adaptive-bubble behavioral perception

A Simple Blood Microdialysis in Freely-Moving Rats for Pharmacokinetic–pharmacodynamic Modeling Study of Shengmai Injection with Simultaneous Determination of Drug Concentrations and Efficacy Levels in Dialysate

A fiber optic photoacoustic sensor for real-time heparin monitoring

In Vitro Anticoagulation Monitoring of Low-Molecular-Weight Heparin

Development of an Ultrasensitive Competitive Double-Enzyme Cascade Fluorescence Signal Amplification Method for Factor XIa Inhibitor Screening

Label-free and Dynamic Monitoring of Endothelial Barrier Function on Microelectronic Cell Sensor Arrays

Monitoring the efficiency of reversal on anti-Xa direct oral anticoagulants using point-of-care viscoelastic testing

Development of a Rapid Qualitative Screen for Anticoagulant Presence

Drug evaluations using a novel microphysiometer based on cell-based biosensors

Electrochemical microfluidic chip based on molecular imprinting technique applied for therapeutic drug monitoring

Streaming-enhanced, chip-based biosensor with acoustically active, biomarker-functionalized micropillars: A case study of thrombin detection

Application of anti-Xa assay in monitoring unfractionated heparin therapy in contemporary antithrombotic management

A Microfluidic Platform With Digital Readout And Ultra-Low Detection Limit For Quantitative Point-Of-Care Diagnostics

Continuous Monitoring of Bisulfide Variation in Microdialysis Effluents by On-Line Droplet-Based Microfluidic Fluorescent Sensor.

Heparin-Bead Extraction Enhanced Fluorogenic Aptamer-Thrombin Composite Reporter Enables Sensitive and Rapid Detection of Functional Antithrombin

Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak–Trough Levels in an Asian Population: A Multicenter Study

A Microfluidic Platform with an Embedded Miniaturized Electrochemical Sensor for On-Chip Plasma Extraction Followed by In Situ High-Sensitivity C-Reactive Protein (hs-CRP) Detection

Electrochemical Disposable Biosensor to Monitor Dabigatran in Point-of-Care Anticoagulation Therapy

Integrative Wireless Device for Remote Continuous Blood Biomarker Monitoring

A highly sensitive and specific fluorescent probe for thrombin detection and high-throughput screening of thrombin inhibitors in complex matrices